Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Moderate Buy” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.40.

Several research analysts recently commented on IRWD shares. Leerink Partners started coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $12.00 to $4.00 in a report on Thursday, August 8th. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Wells Fargo & Company cut their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $4.78 on Tuesday. The stock has a market cap of $763.56 million, a P/E ratio of -159.33 and a beta of 0.47. Ironwood Pharmaceuticals has a one year low of $3.79 and a one year high of $15.70. The stock has a fifty day moving average price of $4.32 and a 200 day moving average price of $5.58.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period last year, the business earned $0.12 earnings per share. Equities research analysts anticipate that Ironwood Pharmaceuticals will post 0.26 EPS for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its stake in shares of Ironwood Pharmaceuticals by 244.8% in the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock valued at $6,775,000 after buying an additional 552,227 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at $693,000. First Eagle Investment Management LLC increased its stake in shares of Ironwood Pharmaceuticals by 10.5% in the first quarter. First Eagle Investment Management LLC now owns 1,002,225 shares of the biotechnology company’s stock valued at $8,729,000 after buying an additional 95,000 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Ironwood Pharmaceuticals by 339.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 195,057 shares of the biotechnology company’s stock worth $1,699,000 after purchasing an additional 150,663 shares during the period. Finally, Edgestream Partners L.P. acquired a new stake in Ironwood Pharmaceuticals in the first quarter worth about $2,581,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.